EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Nanomedicine Meets Immunotherapy: Advancing Adoptive Cell Therapy with Nanoparticles in the Treatment of Cancer with Sustainability Perspectives

Erica Frostegård, Tatiana Bobrova, Amalie Leinebø, Thibault Leray, Shayamita Ghosh, Lorena García-Hevia, Chiara Puccinelli, Lorenzo Riccio, Jacopo Sorani, Davide Bonifazi, Julien Caumartin, Emmanuel Donnadieu und 8 weitere

Advanced Science · 2026

DOI: 10.1002/advs.202522864 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Advanced Science, 2026. Verfasst von Erica Frostegård und 19 weiteren Autor:innen. Beteiligte Einrichtung: CNRS, Immunology, Immunopathology and Therapeutic Chemistry, UPR 3572, University of Strasbourg, Strasbourg, France. Hauptthemen laut MEDLINE: Neoplasms, Nanomedicine, Nanoparticles, Immunotherapy, Adoptive. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 325 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Research and Innovation Program (Marie Skłodowska-Curie Actions - Doctoral Networks), Swiss State Secretariat for Education, Research and Innovation, Centre National de la Recherche Scientifique.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Immunotherapy has achieved remarkable clinical success in certain cancers, particularly through adoptive cell therapy (ACT), where T cell engineering with chimeric antigen receptor (CAR) has driven major clinical breakthroughs in the treatment of hematologic malignancies. However, efficacy against solid tumors remains limited due to multiple barriers, including the scarcity of tumor‐specific antigens, antigen heterogeneity, immunosuppressive tumor microenvironment, and physical obstruction of T cell infiltration by dense extracellular matrix. Nanoparticle (NP)‐based approaches can overcome these obstacles and enhance ACT by improving tumor immunogenicity and vascular permeability, while reducing off‐target toxicity to healthy tissues. This review discusses different strategies leveraging NPs to enhance ACT, including the delivery of immunomodulators and chemotherapeutics, NP‐mediated hyperthermia, magnetic guidance to improve T cell accumulation in tumors, and in vivo NP‐mediated generation and activation of CAR T cells. While prioritizing patient safety is essential, it does not fully reflect the range of risks and challenges associated with novel nanomedicines. In this regard, we discuss how integrating environmental impact assessments early in the development process is crucial for identifying key impact areas of concern and steering innovation towards more sustainable and responsible designs. Finally, we also identify current challenges, and discuss potential solutions and future research directions, including safety and sustainability.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeoplasmsNanomedicineNanoparticlesImmunotherapy, AdoptiveImmunotherapyHumansAnimalsTumor MicroenvironmentT-LymphocytesReceptors, Chimeric Antigen

Stichwörter der Autor:innen

chimeric antigen receptordrug deliveryimmunomodulatormagnetic hyperthermiaphotothermal therapy

Substanzen

Receptors, Chimeric Antigen

Autor:innen und Institutionen

  • CNRS, Immunology, Immunopathology and Therapeutic Chemistry, UPR 3572, University of Strasbourg, Strasbourg, France.
  • INSERM UMR 1186, Integrative Tumor Immunology and Immunotherapy, Gustave Roussy, Fac. de Médecine-University Paris-Sud, Université Paris-Saclay, Villejuif, France.
  • University of Paris City, CNRS, Inserm, NABI, Paris, France.
  • Translational Research Unit, Section for Cellular Therapy, Department of Oncology, Oslo University Hospital, Oslo, Norway.
  • Medical Faculty, University of Oslo, Oslo, Norway.
  • The Nanomedicine Group, Universidad de Cantabria-Instituto de Investigación Valdecilla-IDIVAL Avda Herrera Oria s/n, Santander, Spain.

ORCID-Profile: Cécilia Ménard-Moyon

Förderung

  • Research and Innovation Program (Marie Skłodowska-Curie Actions - Doctoral Networks)
  • Swiss State Secretariat for Education, Research and Innovation
  • Centre National de la Recherche Scientifique
  • Agence Nationale de la Recherche
  • Interdisciplinary Thematic Institute SysChem via IdEx Unistra
  • Spanish Instituto de Salud Carlos III
  • L.G.H.
  • European Regional Development Fund, and IDIVAL

Zitieren

APA

Frostegård, E., Bobrova, T., Leinebø, A., Leray, T., Ghosh, S., García-Hevia, L., Puccinelli, C., Riccio, L., Sorani, J., Bonifazi, D., Caumartin, J., Donnadieu, E., Gazeau, F., Hischier, R., Inderberg, E. M., Fanarraga, M. L., Loustau, M., Nowack, B., Wälchli, S., & Ménard-Moyon, C. (2026). Nanomedicine Meets Immunotherapy: Advancing Adoptive Cell Therapy with Nanoparticles in the Treatment of Cancer with Sustainability Perspectives. Advanced Science. https://doi.org/10.1002/advs.202522864

Vancouver

Frostegård E, Bobrova T, Leinebø A, Leray T, Ghosh S, García-Hevia L, et al. Nanomedicine Meets Immunotherapy: Advancing Adoptive Cell Therapy with Nanoparticles in the Treatment of Cancer with Sustainability Perspectives. Advanced Science. 2026. doi:10.1002/advs.202522864

BibTeX
@article{Frostegrd2026,
  author = {Frostegård, Erica and Bobrova, Tatiana and Leinebø, Amalie and Leray, Thibault and Ghosh, Shayamita and García-Hevia, Lorena and Puccinelli, Chiara and Riccio, Lorenzo and Sorani, Jacopo and Bonifazi, Davide and Caumartin, Julien and Donnadieu, Emmanuel and Gazeau, Florence and Hischier, Roland and Inderberg, Else Marit and Fanarraga, Mónica L and Loustau, Maria and Nowack, Bernd and Wälchli, Sébastien and Ménard-Moyon, Cécilia},
  title = {Nanomedicine Meets Immunotherapy: Advancing Adoptive Cell Therapy with Nanoparticles in the Treatment of Cancer with Sustainability Perspectives},
  journal = {Advanced Science},
  year = {2026},
  doi = {10.1002/advs.202522864}
}
Kostenlos starten →